AP301, an orally inhaled drug candidate is used against respiratory failure caused by pulmonary oedema that activates lung oedema reabsorption.
The Phase I single-center clinical trial assessed the safety, tolerability and pharmacokinetic profile of AP301 in an orally inhaled, double-blind, randomized, placebo-controlled, dose escalation study in 48 healthy male volunteers.
The data demonstrated that the drug was safe and well-tolerated at all doses.